COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN IN THE TREATMENT OF INVASIVE CANDIDA INFECTION IN CHINA

被引：0
|
作者：
Wang, C. [1 ]
Dong, H. [1 ]
Sun, L. [1 ]
机构：
[1] Shenyang Pharmaceut Univ, Shenyang, Peoples R China
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.1604
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN61
引用
收藏
页码：A275 / A276
页数：2
相关论文
共 50 条
  • [1] MICAFUNGIN VERSUS CASPOFUNGIN FOR THE TREATMENT OF SYSTEMIC CANDIDA INFECTIONS: A COST-EFFECTIVENESS ANALYSIS FOR SWITZERLAND
    Felder, S.
    Mayrhofer, T.
    VALUE IN HEALTH, 2014, 17 (03) : A275 - A275
  • [2] A COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN FOR TREATMENT OF SYSTEMIC CANDIDA INFECTIONS IN ITALY
    Sidhu, M. K.
    Van Engen, A. K.
    Switjnk, A. B.
    Concia, E.
    VALUE IN HEALTH, 2009, 12 (07) : A425 - A425
  • [3] Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK
    Sidhu, M. K.
    van Engen, A. K.
    Kleintjens, J.
    Schoeman, O.
    Palazzo, M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (08) : 2049 - 2059
  • [4] MICAFUNGIN VS CASPOFUNGIN FOR THE TREATMENT OF SYSTEMIC CANDIDA INFECTIONS: A COST-EFFECTIVENESS ANALYSIS FOR GERMANY
    Felder, S.
    Grabe, K.
    Mayrhofer, T.
    Decker, S.
    VALUE IN HEALTH, 2009, 12 (07) : A426 - A427
  • [5] Micafungin versus caspofungin in the treatment of Candida glabrata infection: a case report
    Yamada S.M.
    Tomita Y.
    Yamaguchi T.
    Matsuki T.
    Journal of Medical Case Reports, 10 (1) : 1 - 5
  • [6] COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS AMPHOTERICIN B, VORICONAZOLE, AND ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS
    Verheggen, B. G.
    Heeg, B. M. S.
    Vos, C. B. J.
    Van Hout, B. A.
    VALUE IN HEALTH, 2008, 11 (06) : A437 - A437
  • [7] THE COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN VERSUS CASPOFUNGIN FOR CANDIDEMIA AND INVASIVE CANDIDIASIS TREATMENT: AN EXPERIENCE FROM IRAN
    Afzali, M.
    Zartab, S.
    Zaboli, P.
    Nikfar, S.
    Boorboor, M.
    VALUE IN HEALTH, 2018, 21 : S229 - S229
  • [8] COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF PAEDIATRIC PATIENTS WITH SYSTEMIC CANDIDA INFECTIONS
    Odeyemi, A.
    Hart, W. M.
    Odeyemi, I. I.
    Musingarimi, P.
    VALUE IN HEALTH, 2010, 13 (03) : A189 - A189
  • [9] Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China
    Chen, Dechang
    Wan, Xianyao
    Kruger, Eliza
    Chen, Can
    Yue, Xiaomeng
    Wang, Liang
    Wu, Jiuhong
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (03) : 301 - 307
  • [10] COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS VORICONAZOLE IN THE EMPIRICAL ANTIFUNGAL THERAPY OF FEBRILE NEUTROPENIA IN CHINA
    Wei, Y.
    Chen, Y.
    Guo, Z.
    VALUE IN HEALTH, 2016, 19 (07) : A911 - A911
12345